S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Forecast, Price & News

$1.00
-0.01 (-0.99%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.99
▼
$1.03
50-Day Range
$0.88
▼
$1.14
52-Week Range
$0.86
▼
$8.77
Volume
16,792 shs
Average Volume
39,914 shs
Market Capitalization
$44.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Senti Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
350.0% Upside
$4.50 Price Target
Short Interest
Bearish
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Senti Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($0.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

641st out of 987 stocks

Biological Products, Except Diagnostic Industry

105th out of 160 stocks

See Top Rated MarketRank™ Stocks Here

SNTI stock logo

About Senti Biosciences (NASDAQ:SNTI) Stock

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Stock News Headlines

June 10, 2023 | americanbankingnews.com
Contrasting Senti Biosciences (SNTI) & The Competition
June 5, 2023 | finance.yahoo.com
Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely
June 10, 2023 | Vantage Point (Ad)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
June 4, 2023 | americanbankingnews.com
Head-To-Head Comparison: Seagen (NASDAQ:SGEN) versus Senti Biosciences (NASDAQ:SNTI)
May 25, 2023 | americanbankingnews.com
Critical Survey: Senti Biosciences (SNTI) and The Competition
May 24, 2023 | americanbankingnews.com
Senti Biosciences (SNTI) & Its Rivals Financial Review
May 11, 2023 | msn.com
Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation
May 9, 2023 | finance.yahoo.com
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
June 10, 2023 | Vantage Point (Ad)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
May 2, 2023 | finance.yahoo.com
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
April 17, 2023 | finance.yahoo.com
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
April 14, 2023 | finance.yahoo.com
Senti Bio to Participate in Upcoming Investor Conferences
March 25, 2023 | americanbankingnews.com
Senti Biosciences (NASDAQ:SNTI) PT Lowered to $2.00
March 24, 2023 | markets.businessinsider.com
Expert Ratings for Senti Biosciences
March 24, 2023 | markets.businessinsider.com
Morgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)
March 24, 2023 | americanbankingnews.com
Senti Biosciences (NASDAQ:SNTI) Price Target Lowered to $7.00 at Chardan Capital
March 24, 2023 | benzinga.com
Senti Biosciences Stock (NASDAQ:SNTI), Dividends
March 23, 2023 | finanznachrichten.de
Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
March 22, 2023 | finance.yahoo.com
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
March 14, 2023 | finance.yahoo.com
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
February 6, 2023 | finance.yahoo.com
Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year
February 1, 2023 | finance.yahoo.com
Senti Bio to Present at the SVB Securities Global Biopharma Conference
January 30, 2023 | msn.com
Chardan Capital Maintains Buy Rating for Senti Biosciences: Here's What You Need To Know
January 27, 2023 | marketwatch.com
Senti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024
January 27, 2023 | finance.yahoo.com
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
December 27, 2022 | finance.yahoo.com
We Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth Carefully
December 19, 2022 | finance.yahoo.com
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
See More Headlines

SNTI Price History

SNTI Company Calendar

Last Earnings
3/22/2023
Today
6/10/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNTI
CUSIP
N/A
CIK
1854270
Web
www.sentibio.com
Phone
650-239-2030
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+350.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,210,000.00
Net Margins
-1,457.24%
Pretax Margin
-1,457.24%
Return on Equity
-48.76%
Return on Assets
-35.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.26
Quick Ratio
6.26

Sales & Book Value

Annual Sales
$4.29 million
Price / Sales
10.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.90 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
44,170,000
Free Float
40,590,000
Market Cap
$44.17 million
Optionable
Not Optionable
Beta
2.48

Key Executives

  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Co-founder, CEO, Pres & Director
    Comp: $811.26k
  • Dr. James J. Collins Ph.D. (Age 57)
    Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
    Comp: $41.49k
  • Dr. Deborah A. Knobelman Ph.D. (Age 49)
    CFO, Head of Corp. Devel. & Treasurer
    Comp: $600.22k
  • Ms. Susan D. Berland (Age 68)
    Sr. Financial Exec. & Independent Director
    Comp: $54.23k
  • Dr. Kanya Rajangam M.D. (Age 49)
    Ph.D., Head of R&D and Chief Medical Officer
    Comp: $679.71k
  • Dr. Philip Lee Ph.D. (Age 41)
    Co-Founder & CTO
  • Dr. Wilson Wong Ph.D.
    Scientific Co-Founder & Member of Scientific Advisory Board
  • Susan Kahlert
    Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SNTI Stock - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares.
View SNTI analyst ratings or view top-rated stocks.

What is Senti Biosciences' stock price forecast for 2023?

4 brokerages have issued 1 year price targets for Senti Biosciences' stock. Their SNTI share price forecasts range from $2.00 to $7.00. On average, they anticipate the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 350.0% from the stock's current price.
View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts.

How have SNTI shares performed in 2023?

Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 29.1% and is now trading at $1.00.
View the best growth stocks for 2023 here.

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SNTI earnings forecast.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.05. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $1.92 million. Senti Biosciences had a negative trailing twelve-month return on equity of 48.76% and a negative net margin of 1,457.24%.

What ETFs hold Senti Biosciences' stock?

ETFs with the largest weight of Senti Biosciences (NASDAQ:SNTI) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).

What is Senti Biosciences' stock symbol?

Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI."

Who are Senti Biosciences' major shareholders?

Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.85%), ARK Investment Management LLC (4.31%) and Triatomic Management LP (0.48%).
View institutional ownership trends.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Senti Biosciences' stock price today?

One share of SNTI stock can currently be purchased for approximately $1.00.

How much money does Senti Biosciences make?

Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $44.17 million and generates $4.29 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Senti Biosciences have?

The company employs 122 workers across the globe.

How can I contact Senti Biosciences?

Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio.

This page (NASDAQ:SNTI) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -